Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson's Disease
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Accumulating evidence supports a role for the immune system in the pathogenesis of Parkinson's disease. Importantly, recent preclinical studies are now suggesting a specific contribution of inflammation to the α-synuclein-induced pathology seen in this condition. METHODS: We used flow cytometry and western blots to detect toll-like receptor 2 and 4 expression in blood and brain samples of Parkinson's disease patients and mice overexpressing human α-synuclein. To further assess the effects of α-synuclein overexpression on the innate immune system, we performed a longitudinal study using Thy1.2-α-synuclein mice that expressed a bicistronic DNA construct (reporter genes luciferase and green fluorescent protein) under the transcriptional control of the murine toll-like receptor 2 promoter. RESULTS: Here, we report increases in toll-like receptors 2 and 4 expression in circulating monocytes and of toll-like receptor 4 in B cells and in the caudate/putamen of Parkinson's disease patients. Monthly bioluminescence imaging of Thy1.2-α-synuclein mice showed increasing toll-like receptor 2 expression from 10 months of age, although no change in toll-like receptor 2 and 4 expression was observed in the blood and brain of these mice at 12 months of age. Dexamethasone treatment starting at 5 months of age for 1 month significantly decreased the microglial response in the brain of these mice and promoted functional recovery as observed using a wheel-running activity test. CONCLUSION: Our results show that toll-like receptors 2 and 4 are modulated in the blood and brain of Parkinson's disease patients and that overexpression of α-synuclein leads to a progressive microglial response, the inhibition of which has a beneficial impact on some motor phenotypes of an animal model of α-synucleinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Parkinson’s disease (PD) patients. (A-B) Western blot quantification of TLR2, TLR4, and molecules involved in their downstream pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], nuclear factor κB [NF-κB]in the striatum of PD patients (n=7) compared to age- and gender-matched controls (CTL or C) (n=6). Data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. *P<.05; **P<.01.](https://figures.cochat.ai/paper-figures/4699b87a783b4139b5544152384eeb27/toll-like-receptor-expression-in-the-blood-and-brain-of-patients-and-a-mouse-figure-2.jpg)
![Figure 3. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Thy1.2-α-synuclein (αSyn)× TLR2-GFP-fluc mice. Schematic diagram of the Thy1.2-αSyn (Rockenstein et al., 2002) and TLR2-GFP-fluc (Lalancette-Hebert et al., 2009) constructs that were used to generate the Thy1.2-αSyn×TLR2-GFP-fluc mice. (B) Immunofluorescent staining of human αSyn (hαSyn) showing none in a littermate nontransgenic for the hαSyn gene and strong expression in the transgenic mouse. Treatment with Proteinase K confirms the presence of αSyn in the substantia nigra of Thy1.2-αSyn×TLR2-GFP-fluc mice. (C) Western blot quantification of TLR2, TLR4, and molecules involved in their pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], Nuclear factor κB [NF-κB]-p65), as well as hαSyn and total αSyn, in the striatum of Thy1.2-αSyn×TLR2-GFP-fluc mice (n=9) compared to wild type×TLR2-GFP-fluc littermates (n=9) at 12 months of age. Western blot data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. hαSyn-/-, TLR2-GFP-fluc mice; hαSyn-/-, Thy1.2-αSyn×TLR2-GFP-fluc mice; SNCA, synuclein, Alpha (Non A4 Component Of Amyloid Precursor); TRIS, TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β (TRIF). Scale bar=100 µm, inset=25 µm, lower row=50 µm.](https://figures.cochat.ai/paper-figures/ab7ba182cb3d400492a3d1aa5bb1d6ba/toll-like-receptor-expression-in-the-blood-and-brain-of-patients-and-a-mouse-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [412]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has been suggested that TLR2 expression is upregulated in PD postmortem human brains.291,292”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [291]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 1×
“All patients had been diagnosed according to the diagnostic criteria of the UK PD Society Brain Bank (Hughes et al., 1992).”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · cited 1×
“The involvement of αSyn to PD pathogenesis is further supported by the fact that overexpression of this protein, as a consequence of either a duplication or triplication of the gene, leads to early-onset PD (Singleton et al., 2003; Chartier-Harlin et al., 2004).”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · cited 1×
“It has in fact long been recognized that PD brains are characterized by the presence of a microglial reaction (McGeer et al., 1988; McGeer and McGeer, 2004), which increases with disease duration (Croisier et al.”
BackgroundWiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029 · cited 1×
“The involvement of αSyn to PD pathogenesis is further supported by the fact that overexpression of this protein, as a consequence of either a duplication or triplication of the gene, leads to early-onset PD (Singleton et al., 2003; Chartier-Harlin et al., 2004).”
BackgroundLang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994 · cited 2×
“In PD, there is a degeneration of the nigrostriatal dopaminergic pathway with formation of Lewy bodies, which together form the pathological hallmarks of the disease (Lang and Lozano, 1998).”
BackgroundMethodZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 1×
“In particular, aggregated forms of this protein secreted by neurons of the substantia nigra (SN) could do this, leading to the production of pro-inflammatory mediators and thereby exacerbating neuronal death (Zhang et al., 2005; Su et al., 2008; Theodore et al., 2008; Lee et al., 2010).”
BackgroundKim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 3×
“It has recently been reported that oligomers of Syn, but not aggregates, can act as TLR2 ligands (Kim et al., 2013).”
BackgroundInfluentialMicroglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843 · cited 1×
“For commercial re-use, please contact journals.permissions@oup.com Background: Accumulating evidence supports a role for the immune system in the pathogenesis of Parkinson’s disease.”
Background
Research works printed but not linked: 1
- 2013, 4, 23
Cited by
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“It has been suggested that TLR2 expression is upregulated in PD postmortem human brains.(291,292) α-synuclein released from neurons can act as an endogenous DAMPs, bind to TLR2, and then be endocytosed and transported to lysosomes for degradation or spreading to adjacent cells.”
BackgroundThe Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease
Sun, M.-F., & Shen, Y.-Q. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.004 · Cited by 445
Exploring Braak’s hypothesis of Parkinson’s disease
Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J. A., & Kraneveld, A. D. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00037 · Cited by 395
Toll-like receptors in the pathogenesis of neuroinflammation
Kumar, V. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.03.012 · Cited by 331
Dodiya, H. B., Forsyth, C. B., Voigt, R. M., Engen, P. A., Patel, J., Shaikh, M., Green, S. J., Naqib, A., Roy, A., Kordower, J. H., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.012 · Cited by 305
Role of Microglia TLRs in Neurodegeneration
Fiebich, B. L., Batista, C. R. A., Saliba, S. W., Yousif, N. M., & de Oliveira, A. C. P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00329 · Cited by 291
Drouin‐Ouellet, J., Sawiak, S. J., Cisbani, G., Lagacé, M., Kuan, W., Saint‐Pierre, M., Dury, R. J., Alata, W., St‐Amour, I., Mason, S. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24406 · Cited by 288
“processed to extract proteins for Western blotting according to previously published protocols.(26) For the multiplex assay, samples were simultaneously analyzed for 9 human markers associated with angiogenesis and BBB permeability, using a Q-Plex Human Angiogenesis assay (Quansys Bioscience, Logan, UT).”
MethodSelf-citationTLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Luchner, M., Reinke, S., & Milicic, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020142 · Cited by 285
The role of Toll-like receptors and neuroinflammation in Parkinson’s disease
Heidari, A., Yazdanpanah, N., & Rezaei, N. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02496-w · Cited by 275
Periphery and brain, innate and adaptive immunity in Parkinson’s disease
Harms, A. S., Ferreira, S. A., & Romero-Ramos, M. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02268-5 · Cited by 272
Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K., & Williams-Gray, C. H. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01083-5 · Cited by 189
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 187
“Several studies have shown that PD is closely associated with TLRs. Patients with PD show elevated blood and brain levels of TLR2 and TLR4 [158].”
BackgroundMicroglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinson’s Disease?
Janda, E., Boi, L., & Carta, A. R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00144 · Cited by 180
“Both the TLR2 and TLR4 were elevated in peripheral immune cells and in PD brain, where TLR2 colocalized with microglia (Doorn et al., 2014; Drouin-Ouellet et al., 2014).”
Immune system responses in Parkinson's disease: Early and dynamic
Tansey, M. G., & Romero‐Ramos, M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14290 · Cited by 178
Hughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Gagliano, S. A., Gandhi, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1907-y · Cited by 177
“TLRs are also upregulated in the brains of patients with PD [12].”
BackgroundThe immune system in Parkinson's disease: what we know so far
Roodveldt, C., Bernardino, L. I., Çakmak, Ö. Ö., Dragić, M., Fladmark, K. E., Ertan, S., Aktaş, B., Pita, C., Ciglar, L., Garraux, G., et al. (2024) · Brain · doi:10.1093/brain/awae177 · Cited by 173
Guo, Z., Lou, Y., Kong, M., Luo, Q., Liu, Z., & Wu, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061463 · Cited by 162
“The expression levels of TLR2 and TLR4 significantly increased in the blood and brain of PD patients [199].”
BackgroundKim, C., Spencer, B., Rockenstein, E., Yamakado, H., Mante, M., Adame, A., Fields, J. A., Masliah, D., Iba, M., Lee, H.-J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0276-2 · Cited by 157
“While the numbers of TLR2 positive microglia cells were increased in the brains of PD/DLB patients and mouse models [7, 34, 53], we were not able to observed extensive microglial α-synuclein deposition in our current in vivo study.”
BackgroundLi, Y., Peng, Y., Shen, Y., Zhang, Y., Liu, L., & Yang, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2076064 · Cited by 156
Tu, H., Yuan, B., Hou, X., Zhang, X., Pei, C., Ma, Y., Yang, Y., Fan, Y., Qin, Z., Liu, C., et al. (2021) · Aging Cell · doi:10.1111/acel.13522 · Cited by 152
Toll-like receptors and their therapeutic potential in Parkinson’s disease and α-synucleinopathies
Kouli, A., Horne, C. B., & Williams-Gray, C. H. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.042 · Cited by 143
Understanding multifactorial architecture of Parkinson’s disease: pathophysiology to management
Kaur, R., Mehan, S., & Singh, S. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3585-x · Cited by 126
Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2
Xia, Y., Zhang, G., Kou, L., Yin, S., Han, C., Hu, J., Wan, F., Sun, Y., Wu, J., Li, Y., et al. (2021) · Brain · doi:10.1093/brain/awab122 · Cited by 123
Wijeyekoon, R., Kronenberg‐Versteeg, D., Scott, K. M., Hayat, S., Kuan, W., Evans, J., Breen, D. P., Cummins, G. A., Jones, J., Clatworthy, M. R., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.01.018 · Cited by 112
“Studies have specifically found increased numbers of classical monocytes, increased monocyte CCR2, TLR2 and TLR4 expression (Funk et al., 2013; Drouin-Ouellet et al., 2015), enhanced phagocytosis (Grozdanov et al.”
BackgroundResultSelf-citationTLR2 and TLR4 in Parkinson’s disease pathogenesis: The environment takes a toll on the gut
Gorecki, A. M., Anyaegbu, C. C., & Anderton, R. S. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00271-0 · Cited by 103
“TLR4 levels throughout the intestinal epithelium and in the wider body are also elevated in PD [48, 60], indicating perturbed regulation.”
BackgroundHughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Taliun, S. A. G., Gandhi, S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1919-7 · Cited by 100
Neuroinflammatory Responses and Parkinson’ Disease: Pathogenic Mechanisms and Therapeutic Targets
Yang, L., Mao, K., Yu, H., & Chen, J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09926-7 · Cited by 97
“Moreover, overexpression of α-synuclein increases microglial activation in vivo (Drouin-Ouellet et al. 2014).”
BackgroundYang, J., Jia, M., Zhang, X., & Wang, P. (2018) · Phytotherapy Research · doi:10.1002/ptr.6221 · Cited by 96
Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2
Kim, C., Lee, H.-J., Masliah, E., & Lee, S.-J. (2016) · Experimental Neurobiology · doi:10.5607/en.2016.25.3.113 · Cited by 92
TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson’s disease
Shao, Q.-H., Chen, Y., Li, F.-F., Wang, S., Zhang, X., Yuan, Y., & Chen, N. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0280-2 · Cited by 89
Innate immune responses to paraquat exposure in a Drosophila model of Parkinson’s disease
Maitra, U., Scaglione, M., Chtarbanova, S., & O’Donnell, J. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-48977-6 · Cited by 85
Guo, T.-T., Zhang, Z., Sun, Y., Zhu, R.-Y., Wang, F.-X., Ma, L.-J., Jiang, L., & Liu, H.-D. (2023) · Nutrients · doi:10.3390/nu15040930 · Cited by 82
“For instance, patients with PD show elevated TLR4 protein levels in their colonic biopsies, circulating monocytes, as well as postmortem caudate and putamen samples [66,67].”
BackgroundIntestinal Inflammation and Parkinson’s Disease
Li, Y., Chen, Y., Jiang, L., Zhang, J., Tong, X., Chen, D., & Le, W. (2021) · Aging and Disease · doi:10.14336/ad.2021.0418 · Cited by 80
“LPS is a primary ligand for TLR4, and it has been shown that TLR4 is elevated in the brain of PD patients [66].”
BackgroundUpregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease
Kasen, A., Houck, C., Burmeister, A. R., Sha, Q., Brundin, L., & Brundin, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105654 · Cited by 78
“of TLR2 and TLR4, indicating a potential systemic proinflammatory state (Drouin-Ouellet et al., 2015; Wijeyekoon et al., 2020).”
Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2
Vitola, P. L., Balducci, C., Cerovic, M., Santamaria, G., Brandi, E., Grandi, F., Caldinelli, L., Colombo, L., Morgese, M. G., Trabace, L., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.02.012 · Cited by 77
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies
Terkelsen, M. H., Klæstrup, I. H., Hvingelby, V. S., Lauritsen, J., Pavese, N., & Romero‐Ramos, M. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223245 · Cited by 72
Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease
Williams, G. P., Schonhoff, A. M., Sette, A., & Arlehamn, C. S. L. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223241 · Cited by 71
“In PD, microglia not only display morphologies indicative of activation, but also have been shown to express markers of inflammation such as HLA-DR [8], CD68 [9], TLR4 [10], and NLRP3 [11].”
BackgroundXie, X., Luo, X., Liu, N., Li, X., Lou, F., Zheng, Y., & Ren, Y. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13972 · Cited by 64
“On the other hand, monocytes in PD patients present impaired function and changed subpopulation (Drouin-Ouellet et al. 2015; da Silva et al. 2016).”
BackgroundCaplan, I. F., & Maguire‐Zeiss, K. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00417 · Cited by 71
“Additional support for a role of TLR2-mediated inflammation in Parkinson’s disease comes from Droiun-Ouellet et al., where TLR2 expression was increased in circulating monocytes of Parkinson’s patients (Drouin-Ouellet et al., 2015).”
BackgroundLorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
“Evidence from human studies reporting that TLR2 and TLR4 expression is increased in blood and brain samples of PD patients [180], and from animal studies in TLR4-KO mice treated with rotenone [172], strengthen the important role that TLR4 may play in intestinal and brain inflammation.”
BackgroundNissen, S. K., Farmen, K., Carstensen, M., Schulte, C., Goldeck, D., Brockmann, K., & Romero‐Ramos, M. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.01.005 · Cited by 69
Valera, E., Mante, M., Anderson, S., Rockenstein, E., & Masliah, E. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0320-x · Cited by 66
“It has been suggested that activation of TLRs might lead to NF-κB translocation to the nucleus and expression of pro-inflammatory genes [42], and evidence supports a role for signaling downstream of TLRs in PD [43, 19, 44, 45].”
BackgroundMicroglial Responses to Brain Injury and Disease: Functional Diversity and New Opportunities
Lyu, J., Jiang, X., Leak, R. K., Shi, Y., Hu, X., & Chen, J. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00857-2 · Cited by 67
Kim, T., Song, S., Park, Y., Kang, S., & Seo, H. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.4.504 · Cited by 66
“TLR2 expression level was increased in the striatum of advanced PD patients [44] and in the substantia nigra and the hippocampus in the early stage of PD patients [45].”
BackgroundInflammasome Signaling in the Aging Brain and Age-Related Neurodegenerative Diseases
Brahadeeswaran, S., Sivagurunathan, N., & Latchoumycandane, C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02683-5 · Cited by 65
“The expression of toll-like receptor-2 (TLR) and toll-like receptor-4 is elevated in the brain and blood samples of patients with PD due to the deposition of α-synuclein [59].”
BackgroundAcuña, L., Hamadat, S., Corbalán, N. S., González-Lizárraga, F., dos-Santos-Pereira, M., Rocca, J., Sepúlveda Díaz, J., Del-Bel, E., Papy-García, D., Chehín, R. N., et al. (2019) · Cells · doi:10.3390/cells8080776 · Cited by 62
Rietdijk, C. D., Van Wezel, R. J. A., Garssen, J., & Kraneveld, A. D. (2016) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2015.28 · Cited by 59
“Overexpression of human α-synuclein in mice resulted in microglial activation and an increase in TLR2 expression.[74] Microglia seem to form a crucial link between TLR2 and PD pathology; an idea that is supported by results from cell culture studies: exposure to α-synuclein activates cultured microglia and increases t…”
Li, B., Xu, P., Wu, S., Jiang, Z., Huang, Z., Li, Q., & Chen, D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180330 · Cited by 61
The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
Lucas, K., Morris, G., Anderson, G., & Maes, M. H. J. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150317224645 · Cited by 54
McCarty, M. F., & Lerner, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103624 · Cited by 51
Microbiome-based therapies for Parkinson’s disease
Alam, M., Abbas, K., Mustafa, M., Usmani, N., & Habib, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1496616 · Cited by 50
Quan, P., Li, X., Si, Y., Sun, L., Ding, F. F., Fan, Y., Liu, H., Wei, C., Li, R., Zhao, X. L., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01590-1 · Cited by 49
“Furthermore, TLRs are elevated in the brains of patients with PD [43].”
BackgroundAging modulates microglia phenotypes in neuroinflammation of MPTP-PD mice
Yao, K., & Zhao, Y. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.07.010 · Cited by 49
“2-α-synuclein mice also demonstrated the expression of TLR2 increased from 10months of age (Drouin-Ouellet et al., 2014).”
Nutraceuticals: An integrative approach to starve Parkinson’s disease
Lama, A., Pirozzi, C., Avagliano, C., Annunziata, C., Mollica, M. P., Calignano, A., Meli, R., & Raso, G. M. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100037 · Cited by 45
“…antioxidant and metal-chelating properties were also recognized in other polyphenolic compounds, such as quercetin, theanine (the amino acid analogs), and theaflavin, the catechin derivative able to protect from neuronal damage synergizing with anti-parkinsonian drugs (Dutta and Mohanakumar, 2015).”
BackgroundInflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight
Forloni, G., Vitola, P. L., Cerovic, M., & Balducci, C. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.11.001 · Cited by 45
Balan, I. S., Boero, G., Chéry, S. L., McFarland, M. H., Lopez, A. G., & Morrow, A. L. (2024) · Life · doi:10.3390/life14050582 · Cited by 44
Biomarkers and the Role of α-Synuclein in Parkinson’s Disease
Du, T., Wang, L., Liu, W., Zhu, G., Chen, Y., & Zhang, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.645996 · Cited by 44
“TLR2 and TLR4 expressions increase in postmortem brain tissue from PD patients (Drouin-Ouellet et al., 2014; Dzamko et al., 2017), and TLR2 is strongly localized to α-Syn positive LBs (Dzamko et al.”
BackgroundPossible Link between SARS-CoV-2 Infection and Parkinson’s Disease: The Role of Toll-Like Receptor 4
Conte, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137135 · Cited by 42
“Drouin-Ouellet and co-workers [23] showed that the overexpression of α-SYN induced a critical modulation of TLR4 signaling in the blood and brain of both experimental models and PD patients.”
BackgroundA Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review
Seneff, S., Kyriakopoulos, A. M., Nigh, G., & McCullough, P. A. (2023) · Cureus · doi:10.7759/cureus.34872 · Cited by 41
“Parkinson's patients also have enhanced expression of TLR4 in circulating monocytes and B cells [87].”
BackgroundMariucci, G., Pagiotti, R., Galli, F., Romani, L. R., & Conte, C. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1057-7 · Cited by 40
Samur, D. N., Akçay, G., Yıldırım, S., Özkan, A., Çeker, T., Derin, N., Tanrıöver, G., Aslan, M., Ağar, A., & Özbey, G. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108977 · Cited by 40
The Role of Glial Mitochondria in α-Synuclein Toxicity
Jeon, Y., Kwon, Y., Jo, M., Lee, S., Kim, S., & Kim, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.548283 · Cited by 37
Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model
Yıldırım, S., Özkan, A., Aytaç, G., Ağar, A., & Tanrιöver, G. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.11.011 · Cited by 37
Szabo, M. P., Iba, M., Nath, A., Masliah, E., & Kim, C. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00755-7 · Cited by 37
Conte, C., Ingrassia, A. M. T., Brevé, J. J. P., Bol, J. G. J. M., Huisman, E., van Dam, A., Beccari, T., & van de Berg, W. D. J. (2023) · Cells · doi:10.3390/cells12101368 · Cited by 36
Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies
Kwon, S., Iba, M., Masliah, E., & Kim, C. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.5.547 · Cited by 35
“Additional studies observed profoundly increased TLR2 expression in the brains of synucleinopathies patients and aged animal models [36, 37].”
BackgroundChung, L. Y.-R., Lin, Y., Liu, C., Tai, Y., Lin, H., Lin, C., & Chen, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.845930 · Cited by 33
Sian‐Hülsmann, J., & Riederer, P. F. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-023-02723-5 · Cited by 32
Vora, U., Vyas, V. K., Wal, P., & Saxena, B. (2022) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2022.01026 · Cited by 32
Wang, Y., Feng, G.-Y., Xia, Q., Hu, Y. H., Xu, Y. X. Z., Xiong, L., Chen, Z.-W., Wang, H., Wang, T., & Zhou, X. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1218-5 · Cited by 31
“Moreover, in transgenic mice overexpressing human wildtype SNCA, an approximate threefold elevation of SNCA resulted in memory deficits similar to AD mouse models [28].”
Neuroinflamação na doença de Parkinson
Sousa, A. A. D., Braga, S. A., & Sobrinho, H. M. D. R. (2016) · Revista Estudos - Revista de Ciências Ambientais e Saúde (EVS) · doi:10.18224/est.v43i1.5188 · Cited by 30
Wang, Y., Zhang, X., Chen, F., Chen, L., Wang, J., & Xie, J. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s301531 · Cited by 30
Let’s make microglia great again in neurodegenerative disorders
Guillot‐Sestier, M., & Town, T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1792-x · Cited by 31
A Focus on Astrocyte Contribution to Parkinson’s Disease Etiology
Prunell, G., & Olivera‐Bravo, S. (2022) · Biomolecules · doi:10.3390/biom12121745 · Cited by 29
Hull, A. J., Atilano, M. L., Gergi, L., & Kinghorn, K. J. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0381 · Cited by 30
“Elevated levels of TLR2 and TLR4 expression are observed in brain regions pathologically affected by PD (i.e. SN pars compacta and putamen) and in myeloid cells of the post-mortem brains of PD patients [75,106].”
Carta, A. R., Boi, L., Pisanu, A., Palmas, M. F., Carboni, E., & Simone, A. D. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108685 · Cited by 28
Gut-Derived Sterile Inflammation and Parkinson's Disease
Shannon, K. M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.831090 · Cited by 27
“(E) Photomicrographs of stained toll-like receptor 4 (TLR4)+ cells in lamina propria of the HC (a,b) and PD mucosa (c,d).”
BackgroundInfluentialHow Toll-like receptors influence Parkinson’s disease in the microbiome–gut–brain axis
Zhang, Z., Liu, Z., Lv, A., & Fan, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1154626 · Cited by 27
“Toll-like receptor 2 expression is increased in monocytes in Parkinson’s disease patients (93, 128).”
BackgroundMcCabe, K., Concannon, R. M., McKernan, D. P., & Dowd, E. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.07.007 · Cited by 27
Bidirectional Relation Between Parkinson's Disease and Glioblastoma Multiforme
Mencke, P., Hanss, Z., Boussaad, I., Sugier, P., Elbaz, A., & Krüger, R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00898 · Cited by 27
“It was shown that microglial TLR2 is increased in the substantia nigra and the hippocampus in the early stages of PD, but not during the late stages (138), while another study found that TLR2 is increased in the striatum of advanced PD patients (135).”
BackgroundXia, L., Li, C., Zhao, J., Sun, Q., & Mao, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156150 · Cited by 24
Li, H., Qian, J., Wang, Y., Wang, J., Mi, X., Qu, L., Song, N., & Xie, J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102288 · Cited by 23
The Innate and Adaptive Immune Cells in Alzheimer’s and Parkinson’s Diseases
Huang, B., Zhenxin, Y., Chen, S., Tan, Z., Zong, Z., Zhang, H., & Xiong, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1315248 · Cited by 23
“2-α -Syn mice [42 – 44].”
Olsen, L. K., Cairns, A. G., Ådén, J., Moriarty, N., Cabré, S., Alamilla, V., Almqvist, F., Dowd, E., & McKernan, D. P. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.04.036 · Cited by 22
Mutant huntingtin protein expression and blood–spinal cord barrier dysfunction in huntington disease
Sciacca, G., & Cicchetti, F. (2017) · Annals of Neurology · doi:10.1002/ana.25107 · Cited by 22
“Western Blot Cervical gray or white matter and lumbar gray or white matter frozen sample dissections (approximately 15mg) from HD patients and age-matched healthy controls (see Table) were processed for Western blotting according to previously published protocols.(23) SDS electrophoresis gels were loaded with 20mg of…”
MethodSelf-citationKumari, A., Srivastava, A., Jagdale, P. R., Ayanur, A., & Khanna, V. K. (2023) · NeuroToxicology · doi:10.1016/j.neuro.2023.04.003 · Cited by 21
Tiwari, R. K., Moin, A., Rizvi, S. M. D., Shahid, S. M. A., & Bajpai, P. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00696-6 · Cited by 20
Roy, R., Kumar, D., Bhattacharya, P., & Borah, A. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105803 · Cited by 20
Mercado, G., Käufer, C., Richter, F., & Peelaerts, W. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240195 · Cited by 20
Greenland, J. C., Holbrook, J. A., Kahanawita, L., Camacho, M., Fryer, T. D., Hong, Y. T., & Williams‐Gray, C. H. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.028 · Cited by 18
“This showed significant positive relationships be-tween [ 11 C]-PK11195 BP ND in the substantia nigra and MDS-UPDRS II and III, and [ 11 C]-PK11195 BP ND in the putamen with MDS-UPDRS II and total score (Table 6).”
Dhankhar, J., Agrawal, N., & Shrivastava, A. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577302 · Cited by 18
Choi, J., Polcher, A. A., & Joas, A. (2016) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2016.en-955 · Cited by 18
Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson’s Disease?
Koukoulis, T. F., Beauchamp, L. C., Kaparakis‐Liaskos, M., McQuade, R. M., Purnianto, A., Finkelstein, D. I., Barnham, K. J., & Vella, L. J. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230315 · Cited by 16
“The expression of TLRs is increased in the brain, (particularly in the caudate putamen), blood, and GI of PwP [83, 153].”
BackgroundTLR2 deficiency is beneficial at the late phase in MPTP-induced Parkinson’ disease mice
He, Y., Zhao, J., Dong, H., Zhang, X., Duan, Y., Ma, Y., Yu, M., Fei, J., & Huang, F. P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122171 · Cited by 16
Prion-like propagation of α-synuclein in the gut-brain axis
Chen, Y., Shao, Q.-H., Yuan, Y., & Chen, N. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.002 · Cited by 16
Sánchez, K. E., & Maguire‐Zeiss, K. A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.585544 · Cited by 16
“, 2015) and human PD subjects display elevated expression of TLR2 and TLR4 in peripheral monocytes and brain tissue (Watson et al., 2012; Drouin-Ouellet et al., 2015).”
BackgroundShared Inflammatory Pathology of Stroke and COVID-19
Sánchez, K. E., & Rosenberg, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095150 · Cited by 16
Malathion Neurotoxic Effects on Dopaminergic System in Mice: Role of Inflammation
Ahmed, D. A. M., Rahman, R. H. A., Salama, M., El-Zalabany, L., & El-Harouny, M. (2017) · Journal of Biomedical Sciencies · doi:10.4172/2254-609x.100074 · Cited by 16
“The other two groups received two different anti-inflammatory drugs (purchased from Amriya Company for pharmaceutical industries) in conjunction with malathion for 8 weeks as follows: Group 3 (G3): "malathion+dexamethasone" M+DX-treated group: mice were given malathion plus subcutaneous dexamethasone injection "3 mg/k…”
MethodJiao, F., Zhou, L., & Wu, Z. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07878-x · Cited by 15
Metadata
- Authors
- Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Cicchetti, F.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-07
- Volume
- 18
- Issue
- 6
- Pages
- pyu103-pyu103
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4438545
- OpenAlex
- W2114037757
- Cited by
- 153
- References
- 63
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 21 · 2021: 19 · 2020: 17 · 2019: 12 · 2018: 19 · 2017: 7 · 2016: 6 · 2015: 5
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Parkinson Society Canada
- National Institute for Health and Care Research
- Parkinson's UK
- University of Cambridge
- Imperial College London
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, TLR2, TLR4, alpha-synuclein, neuroinflammation, microglia, innate immunity, circulating monocytes, B cells, caudate-putamen, synucleinopathies, dexamethasone, motor recovery, bioluminescence imaging
- MeSH terms
- Aged, Aged, 80 and over, Animals, Antiparkinson Agents, B-Lymphocytes, Brain, Dexamethasone, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Monocytes, Parkinson Disease, Time Factors, Up-Regulation, Case-Control Studies, Microglia, Green Fluorescent Proteins, Toll-Like Receptors, Toll-Like Receptor 2, Toll-Like Receptor 4, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.